BD Hits 2 Billion Injection Device Milestone In Support Of Global COVID-19 Vaccination Efforts

Company Now Supplying More Than 40 Countries for Pandemic Vaccination Campaigns

フランクリンレイクス、ニュージャージー州, 2021 年 6 月 8 日 / PRNewswire / — BD（ベクトン、ディキンソンアンドカンパニー） (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.

This new milestone reflects commitments to governments across the world, including the United States, Australia, Brazil, カナダ, フランス , ドイツ, India, フィリピン, サウジアラビア, 南アフリカ共和国, スペインとイギリス, among many others, as well as non-governmental organizations supporting vaccine deployment for developing countries. In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners.

“Expanding vaccination efforts are bringing restored hope and a long-awaited return to normalcy in multiple countries around the world,” said リック・バード, president of Medication Delivery Solutions for BD. “We are committed to continuing to support government partners and non-governmental organizations in these efforts to ensure health care providers on the front lines of this crisis have these much-needed injection devices to protect their patients from COVID-19.”

BD has delivered more than 900 million injection devices around the world to date, with the remaining orders to be delivered between now and the end of 2022 to support vaccine administration. These devices are being shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country’s individual distribution and allocation strategy. BD continues to be in discussions with government agencies and non-governmental organizations on the need to plan ahead to ensure supply availability and place orders for delivery in late 2022 and into the future.

As part of its efforts, BD continues to closely plan supply capabilities to help ensure maximum volumes can be dedicated to COVID-19 efforts, while minimizing disruption for routine health care, annual flu vaccinations and childhood immunization programs.

BD has also announced multiple capital investments to expand capacity for vaccination injection devices for COVID-19 and future pandemics. These include:

Adding new manufacturing lines for injection devices in the company’s Fraga, スペイン manufacturing facility. When these lines ramp up now through 2022 it will increase output of these devices by nearly 500 million per year to support COVID-19 and other efforts, mainly for markets in ヨーロッパ, 中東 & アフリカ, as well as for non-governmental organizations.

For this critical role and commitment to support vaccination efforts globally, BD was recently recognized at the 2021 World Vaccine Congress’ Vaccine Industry Excellence Awards as the “Best Production/Process Development.” The award recognized BD for its ability to extend its capacity to provide disposable syringes and pre-fillable syringes required for COVID-19 vaccinations, as well as its range of solutions covering the entire vaccine development.

BD は世界最大の注射装置メーカーであり、世界的な製造ネットワークを通じて年間数十億個の注射器と注射針を生産しています。 BD のワクチン接種準備の取り組みについて詳しくは、次のサイトをご覧ください。 bd.com/ワクチン.

BDについて
BDは世界最大のグローバルメディカルテクノロジー企業の70,000つであり、医療の発見、診断、ケアの提供を改善することにより、健康の世界を推進しています。同社は、患者の臨床治療と医療提供者の臨床プロセスの両方を進歩させるのに役立つ革新的なテクノロジー、サービス、ソリューションを開発することにより、医療の最前線のヒーローをサポートしています。 BDとそのXNUMX人の従業員は、臨床医のケア提供プロセスの安全性と効率を高め、研究者が疾患を正確に検出し、研究者の能力を高めて次世代の診断と治療法を開発できるようにする情熱と取り組みを持っています。 BDは、ほとんどすべての国に存在し、世界中の組織と提携して、最も困難な世界的な健康問題のいくつかに対処しています。 BDはお客様と緊密に連携することで、成果の向上、コストの削減、効率の向上、安全性の向上、ヘルスケアへのアクセスの拡大を支援します。 BDの詳細については、次のWebサイトをご覧ください。 bd.com またはLinkedInで私たちと接続してくださいリンクトイン.com/company/bd1 そしてツイッター @BDandCo.

将来の見通しに関する記述
This press release contains certain forward-looking statements regarding BD’s manufacturing operations and capacity. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, many of which are beyond the company’s control, as discussed in BD’s filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update any such statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.